Amylyx Pharmaceuticals (AMLX) Stock Forecast & Price Target

Amylyx Pharmaceuticals is compelling because avexitide’s Phase 3 LUCIDITY readout was highly significant, cutting the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo with clean safety and all secondary endpoints met, supporting the view that it could become the first-ever treatment for PBH. The company also appears well positioned financially and commercially, with Breakthrough Therapy and Orphan Drug designations, an NDA expected by year-end, and estimates implying about $3.5B in avexitide sales in 2035E and a path to a $10B+ franchise over time. Positive data, an expanded addressable population of roughly 160,000 moderate-to-severe US PBH patients, and follow-on pipeline assets such as AMX0318 strengthen the long-term upside thesis.

Amylyx Pharmaceuticals is highly dependent on a small set of early-stage assets, leaving the investment case vulnerable to clinical setbacks, regulatory delays, and commercialization risk across its pipeline. The cited thesis itself highlights that failure of AMX0035 and avexitide in clinical studies, or failure to secure approval in the US and EU, would materially weaken the outlook, while Phase 3 data in adults with PBH could still miss efficacy or safety expectations. Even the bullish valuation framework relies on distant assumptions, including $7.30 of taxed and diluted 2034 EPS and discounted 2026-2034 cash flows, underscoring how little current fundamental support the stock has today.